-
Italfarmaco Shares Updates Ahead of Givinostat PDUFA Date
Italfarmaco S.p.A. has announced that the full results from the pivotal phase 3 EPIDYS clinical […]
-
7 tips for traveling alone with my 3 sons who have Duchenne
I am traveling this week with my three sons who have Duchenne muscular dystrophy (DMD): […]
-
The Duchenne Registry Has a New Gene Therapy Survey!
Open The Duchenne Registry app and you will notice a new survey on Gene Therapy. […]
-
WATCH: NS Pharma – Overview of New Exon Skipping Trials: Brogidirsen and NS-050/NCNP-03 (Webinar Recording)
NS Pharma recently joined PPMD for a community webinar to share an overview of two […]
-
MDA 2024: Dyne trials raising doses after early positive results
DYNE-251 and DYNE-101, Dyne Therapeutics’ investigational therapies for forms of muscular dystrophy, appear safe and […]
-
MDA 2024: Limb, heart function preserved with DMD cell therapy
The investigational cell therapy CAP-1002 has continued to slow declines in upper limb and heart […]
-
Turning to prayer when thoughts of uselessness creep in
As I write this column, my wife, Wendy, is undergoing abdominal surgery. I won’t go […]
-
Ask Me Anything: Traveling with Duchenne with Marissa Penrod, Adam Malone and Alan Chaulet
This pre-recorded webinar delves into the world of travel with special guests, Marissa Penrod and […]
-
Join Us in Orlando for PPMD’s 30th Annual Conference
Celebrate three decades of progress, community, and resilience at PPMD’s 30th Annual Conference, June 27–29, […]
-
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne
PPMD is pleased to learn of the U.S. commercial launch of AGAMREE® (vamorolone) oral suspension […]
